专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010083495A4 POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN 审中-公开
标题翻译：多肽靶向血管内皮生长因子受体-2和ALPHA V BETA 3 INTEGRIN
公开(公告)号：WO2010083495A4
公开(公告)日：2011-02-10
申请号：PCT/US2010021332
申请日：2010-01-18
申请人： UNIV LELAND STANFORD JUNIOR , COCHRAN JENNIFER R , SILVERMAN ADAM , JONES DOUGLAS , PAPO NIV
发明人： COCHRAN JENNIFER R , SILVERMAN ADAM , JONES DOUGLAS , PAPO NIV
IPC分类号： C07H21/04
CPC分类号： C07K14/515 , A61K38/18 , A61K38/1858 , A61K38/1866 , A61K47/51 , A61K2123/00 , C07K14/475
摘要： Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
摘要翻译：提供了包含变体血管内皮生长因子序列的多肽。该多肽可用于癌症成像，癌症诊断，监测和治疗以及以过度新血管形成为特征的疾病的治疗。

2. 发明申请

WO2010083495A3 POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN 审中-公开
标题翻译：多肽靶向血管内皮生长因子受体-2和ALPHA V BETA 3 INTEGRIN
公开(公告)号：WO2010083495A3
公开(公告)日：2010-12-23
申请号：PCT/US2010021332
申请日：2010-01-18
申请人： UNIV LELAND STANFORD JUNIOR , COCHRAN JENNIFER R , SILVERMAN ADAM , JONES DOUGLAS , PAPO NIV
发明人： COCHRAN JENNIFER R , SILVERMAN ADAM , JONES DOUGLAS , PAPO NIV
IPC分类号： C07H21/04
CPC分类号： C07K14/515 , A61K38/18 , A61K38/1858 , A61K38/1866 , A61K47/51 , A61K2123/00 , C07K14/475
摘要： Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
摘要翻译：提供了包含变体血管内皮生长因子序列的多肽。该多肽可用于癌症成像，癌症诊断，监测和治疗以及以过度新血管形成为特征的疾病的治疗。

3. 发明申请

WO2011091305A3 INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY 审中-公开
标题翻译： AXI信号在抗生素治疗中的抑制作用
公开(公告)号：WO2011091305A3
公开(公告)日：2013-02-21
申请号：PCT/US2011022125
申请日：2011-01-21
申请人： UNIV LELAND STANFORD JUNIOR , GIACCIA AMATO J , RANKIN ERINN BRUNO , COCHRAN JENNIFER R , JONES DOUGLAS , KARIOLIS MIHALIS , FUH KATHERINE , MIAO YU
发明人： GIACCIA AMATO J , RANKIN ERINN BRUNO , COCHRAN JENNIFER R , JONES DOUGLAS , KARIOLIS MIHALIS , FUH KATHERINE , MIAO YU
IPC分类号： C07K14/00
CPC分类号： C07K16/22 , A61K38/179 , C07K14/705 , C07K2319/30
摘要： Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
摘要翻译：提供了通过施用治疗剂量的抑制AXL蛋白活性的药物组合物来减轻哺乳动物癌症的组合物和方法，例如通过竞争性或非竞争性地抑制AXL与其配体GAS6之间的结合相互作用。

4. 发明申请

WO2011116396A3 HEPATOCYTE GROWTH FACTOR FRAGMENTS THAT FUNCTION AS POTENT MET RECEPTOR AGONISTS AND ANTAGONISTS 审中-公开
标题翻译： HEPATOCYTE生长因子片段功能作为MET受体激动剂和拮抗剂
公开(公告)号：WO2011116396A3
公开(公告)日：2012-04-19
申请号：PCT/US2011029271
申请日：2011-03-21
申请人： UNIV LELAND STANFORD JUNIOR , COCHRAN JENNIFER R , JONES DOUGLAS S II , TSAI PING-CHUAN
发明人： COCHRAN JENNIFER R , JONES DOUGLAS S II , TSAI PING-CHUAN
IPC分类号： C07K14/475 , A61K38/18
CPC分类号： C07K14/4753 , A61K38/00
摘要： The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NKl variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NKl variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics.
摘要翻译：肝细胞生长因子（HGF）的NK1片段结合并激活Met受体，一种跨膜受体酪氨酸激酶，在胚胎发育和器官形成过程中起关键作用。本申请公开了作为HGF的激动剂或拮抗剂的NK1变体多肽。进一步公开的是共价连接的NK1变体多肽。所公开的变体多肽中的许多具有改善的稳定性特征。

5. 发明申请

WO2008045252A2 ENGINEERED INTEGRIN BINDING PEPTIDES 审中-公开
标题翻译：工程整合胶粘剂
公开(公告)号：WO2008045252A2
公开(公告)日：2008-04-17
申请号：PCT/US2007021218
申请日：2007-10-03
申请人： UNIV LELAND STANFORD JUNIOR , COCHRAN JENNIFER R , KIMURA RICHARD , LEVIN ARON M , GAMBHIR SANJIV S
发明人： COCHRAN JENNIFER R , KIMURA RICHARD , LEVIN ARON M , GAMBHIR SANJIV S
IPC分类号： C07K16/28
CPC分类号： A61K38/1709 , A61K38/06 , A61K38/08 , A61K45/06 , A61K49/0056 , A61K51/082 , C07K14/47 , G01N33/57492
摘要： Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (a 5 ß 1 ) or vitronectin (a v ß 3 and a v ß 5 integrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation.
摘要翻译：以高亲和力（低平衡解离常数（Kd））结合到纤连蛋白（α5β1S1）的细胞表面受体或玻连蛋白（a < v3＆lt; 3＆gt;和＆lt;＆lt;＆lt;＆lt;＆lt; 5＆gt; 5＆gt; 5）整联蛋白）。这些肽基于其中插入了含有RGD整联蛋白结合基序的子序列的分子支架。子序列（RGD模拟物）包含约9-13个氨基酸，并且子序列内含有的RGD可以侧接多种氨基酸，其序列通过连续的选择轮次（体外进化）确定。分子支架优选基于knottin，例如EETI（胰蛋白酶抑制剂2（胰蛋白酶抑制剂II）（EETI-II）[Ecballium elaterium（跳跃黄瓜）]，AgRP（Agouti相关蛋白）和Agatoxin IVB，该肽具有刚性定义的三维构象。

6. 发明申请

WO2009134414A2 DEVICES FOR THE TREATMENT OF WOUNDS AND METHODS AND KITS THEREOF 审中-公开
标题翻译：用于治疗创伤的装置及其方法及其工具
公开(公告)号：WO2009134414A2
公开(公告)日：2009-11-05
申请号：PCT/US2009002672
申请日：2009-04-29
申请人： UNIV LELAND STANFORD JUNIOR , BECK STAYCE , MYUNG DAVID , FRANK CURTIS W , COCHRAN JENNIFER R , LONGAKER MICHAEL T , YANG GEORGE P , LY DAPHNE P , MANDEL SHIRA G
发明人： BECK STAYCE , MYUNG DAVID , FRANK CURTIS W , COCHRAN JENNIFER R , LONGAKER MICHAEL T , YANG GEORGE P , LY DAPHNE P , MANDEL SHIRA G
IPC分类号： A61L15/22 , A61L15/60
CPC分类号： A61L15/60 , A61L15/225 , C08L71/02
摘要： Interpenetrating network hydrogels are described that may be incorporated into wound dressings and/or in implants. The properties of the interpenetrating network hydrogel may be tuned to control an amount of moisture in a wound environment. The devices, methods, and kits described herein may be adapted to treat a variety of wound types at a variety of healing stages over a range of time scales. Some hydrogels may be configured to deliver one or more vulnerary agents to a wound. The interpenetrating network hydrogels may also be adapted to control a rate and/or amount of moisture uptake so that the hydrogels may be used as expandable implants to expand tissue.
摘要翻译：描述了可以并入伤口敷料和/或植入物中的互穿网络水凝胶。可以调节互穿网络水凝胶的性质以控制伤口环境中的水分量。本文描述的装置，方法和试剂盒可适用于在多个时间范围内的各种愈合阶段处理各种伤口类型。一些水凝胶可以被配置成将一种或多种弱毒剂递送到伤口。互穿网络水凝胶还可以适于控制吸湿的速率和/或量，使得水凝胶可以用作可膨胀植入物以膨胀组织。

7. 发明申请

WO2014035828A3 INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY 审中-公开
标题翻译： AXL信号在抗转移治疗中的抑制作用
公开(公告)号：WO2014035828A3
公开(公告)日：2014-05-01
申请号：PCT/US2013056435
申请日：2013-08-23
申请人： UNIV LELAND STANFORD JUNIOR
发明人： GIACCIA AMATO J , RANKIN ERINN BRUNO , COCHRAN JENNIFER R , JONES DOUGLAS , KARIOLIS MIHALIS , FUH KATHERINE , MIAO YU
IPC分类号： C07K7/08 , C07K14/705
CPC分类号： C07K14/705 , A61K38/00 , A61K45/06 , C07K14/82
摘要： Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
摘要翻译：提供了通过施用治疗剂量的抑制AXL蛋白质活性的药物组合物，例如通过竞争性或非竞争性抑制AXL与其配体GAS6之间的结合相互作用来减轻哺乳动物中的癌症的组合物和方法。

8. 发明公开

EP3259385A4 MICRO-SCREENING APPARATUS, PROCESS, AND PRODUCTS 无效转让
公开(公告)号：EP3259385A4
公开(公告)日：2018-07-25
申请号：EP16753225
申请日：2016-02-22
申请人： UNIV LELAND STANFORD JUNIOR
发明人： BAER THOMAS M , COCHRAN JENNIFER R , CHEN BOB , ALFORD SPENCER CALEB , LIM SUNGWON , KANNAN ARVIND , DIMOV IVAN
IPC分类号： G01N33/543 , C40B30/00 , C40B30/04 , C40B30/06 , C40B30/08 , G01N33/50
CPC分类号： C12N15/1079 , C40B30/06 , C40B30/08 , G01N33/502 , G01N33/5304 , G01N33/54366 , G01N33/54386
摘要： Microcavity arrays and methods for quantitative biochemical and biophysical analysis of populations of biological variants. Examples include high-throughput analysis of cells and protein products use a range of fluorescent assays, including binding-affinity measurement and time-resolved enzyme assays. Laser-based extraction of microcavity contents.

9. 发明申请

WO2016115511A3 VEGF VARIANT POLYPEPTIDE COMPOSITIONS 审中-公开
标题翻译： VEGF变体多肽组合物
公开(公告)号：WO2016115511A3
公开(公告)日：2016-10-06
申请号：PCT/US2016013688
申请日：2016-01-15
申请人： UNIV LELAND STANFORD JUNIOR
发明人： COCHRAN JENNIFER R , KAPUR SHIVEN , BLUMENKRANZ MARK S
IPC分类号： A61K38/00 , A61K38/04 , A61K38/16
CPC分类号： C07K14/52 , A61K38/00 , C07K2319/30
摘要： Provided herein are VEGF variant polypeptides and Fc-VEGF variant polypeptide fusions, comprising a first VEGF monomer joined to a second VEGF monomer by a peptide linker or a disulfide bridge. In some embodiments, the VEGF variant polypeptides comprise the formula: A-L-B, wherein A is a first VEGF monomer subunit; B is a second VEGF monomer subunit; and L is a peptide linker having 14 to 20 amino acids. In certain embodiments, disclosed herein, are methods of treating an angiogenic disorder in an individual in need thereof, comprising administering to the individual a VEGF variant polypeptide or an Fc-VEGF variant polypeptide fusion. In certain embodiments, disclosed herein, are kits comprising a VEGF variant polypeptide or Fc-VEGF variant polypeptides.
摘要翻译：本文提供了VEGF变体多肽和Fc-VEGF变体多肽融合物，其包含通过肽接头或二硫键与第二VEGF单体连接的第一VEGF单体。在一些实施方案中，VEGF变体多肽包含式：A-L-B，其中A是第一VEGF单体亚基; B是第二个VEGF单体亚基; L是具有14-20个氨基酸的肽接头。在本文公开的某些实施方案中，是在有需要的个体中治疗血管发生障碍的方法，包括向个体施用VEGF变体多肽或Fc-VEGF变体多肽融合物。在本文公开的某些实施方案中，是包含VEGF变体多肽或Fc-VEGF变体多肽的试剂盒。

10. 发明公开

EP2638173A4 FUSION PROTEINS COMPRISING AN ENGINEERED KNOTTIN PEPTIDE AND USES THEREOF 有权转让
标题翻译： FUSIONSPROTEINE MIT EINEM MANIPULIERTEN KNOTTINPEPTID UND SEINE VERWENDUNGEN
公开(公告)号：EP2638173A4
公开(公告)日：2014-03-26
申请号：EP11839687
申请日：2011-11-07
申请人： UNIV LELAND STANFORD JUNIOR
发明人： COCHRAN JENNIFER R , JONES DOUGLAS S , KARIOLIS MIHALIS S , TSAI PING-CHUAN
IPC分类号： C12P21/04
CPC分类号： C07K14/705 , C07K14/43518 , C07K14/47 , C07K14/4702 , C07K14/475 , C07K14/71 , C07K14/81 , C07K14/8121 , C07K2319/00
摘要： The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.
摘要翻译：本公开提供了通过结构域添加和进化来设计现有蛋白质 - 蛋白质相互作用的一般方法。该公开内容教导了包含knottin肽的新型融合蛋白的产生，其中一部分knottin肽被用于结合特定靶标而产生的序列替代。这样的融合蛋白也可以是双特异性或多特异性的，因为它们可以结合和/或抑制两种或多种受体或受体配体。 Knottins可以与现有配体（或受体）融合，作为增加配体 - 受体相互作用或产生多特异性蛋白质的亲和力的通用平台。此外，融合蛋白可以包含与另一种蛋白质融合的knottin肽，其中另一种蛋白促进knottin的正确表达和折叠。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式